Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects

NCT02621489 on ClinicalTrials.gov · last registry update 2023-04-20

Finished August 2022, after enrolling 38 people. exenatide is approved in the US, but not for cardiovascular disease and diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Karolinska Institutet
Sponsor type: Other
Enrollment: 38
Started: 2015-12
Primary completion: 2022-08 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

The degree of non-covered stent struts by Bydureon add on to Insulin over that of Insulin as analyzed by optical coherence tomography (OCT).

Conditions studied

Atherosclerosis · Diabetes · Restenosis

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.